A layer of mucus covers the surface of all wet epithelia throughout the human body. Mucus is a hydrogel mainly composed of water, mucins (glycoproteins), DNA, proteins, lipids, and cell debris. This complex composition yields a tenacious viscoelastic hydrogel that lubricates and protects the exposed epithelia from external threats and enzymatic degradation. The natural protective role of mucus is nowadays acknowledged as a major barrier to be overcome in non-invasive drug delivery. The heterogeneity of mucus components offers a wide range of potential chemical interaction sites for macromolecules, while the mesh-like architecture given to mucus by the intermolecular cross-linking of mucin molecules results in a dense network that physically, and in a sizedependent manner, hinders the diffusion of nanoparticles through mucus. Consequently, drug diffusion, epithelial absorption, drug bioavailability, and ultimately therapeutic outcomes of mucosal drug delivery can be attenuated.
Introduction
The mucosal epithelial surfaces across the human body are constantly exposed to the surrounding environment to fulfill vital functions such as breathing, nutrition, sensing, and reproduction. Mucosal tissues are thus readily accessible and represent appealing drug delivery routes for topical as well as for non-invasive systemic delivery [1] [2] [3] . To counterbalance their high level of exposure to the environment, a protective layer of mucus covers the epithelia of the pulmonary airways [4] , the whole gastrointestinal (GI) tract, including the stomach and the small and large intestines [5] , the cervicovaginal tract [6] , and the eyes [7] , among others.
Mucus is a complex hydrogel composed primarily of water (~95%), glycoproteins (mucins,~2-5% w/v), lipids, DNA, non-mucin proteins, and cell debris [8, 9] . Such complex biochemical composition grants mucus the ability to adsorb a wide range of molecules and particles, including drugs, and other potentially harmful entities like pathogens, toxins, and pollutants. The mucus layer is also in constant motion, featuring a dynamic barrier that removes any entrapped material, precluding its contact with the epithelial surface. Nevertheless, the exact mucus composition, pH, layer thickness, and mucus clearance mechanism vary depending on the anatomical origin of mucus, most likely following a developmental strategy to adapt each mucus layer to the specific functions that need to be accomplished in each tissue.
The role of mucus in health encompasses a diverse number of functions. Among them, the protection of the underlying epithelia is a common function in all mucosal tissues. Mucus also has anti-microbial properties [10, 11] , serves as a lubricant in the GI tract [9, 12] , reduces the shear stress during eye-blinking [7] , contributes to humidify the inhaled air, and plays a relevant role in the regulation of the estrous cycle [13] (Table 1) .
Mucins, a family of glycoproteins encoded by some 20 genes synthesized and secreted by epithelial tissues, are the most relevant constituents of mucus [40] . They can be classified into those which form the extracellular mucus hydrogel, gel-forming mucins, and those anchored to the cell membrane, membrane-tethered mucins. The main function of the former mucin type is to protect the epithelial surface, whereas the role of the latter type is related to intracellular signaling and the formation of the glycocalyx [16, 41] . The primary structure of mucins consists of a protein backbone with a high number of tandem repeats of the amino acids proline-serine-threonine (PTS sequences) [8, 42] . The hydroxyl groups of the serine and threonine residues provide sites for the covalent binding of oligosaccharides through O-glycosylation [8, 43] . N-acetylgalactosamine, N-acetylglucosamine, galactose, sialic acid, and fucose have been identified as the predominant residues of the oligosaccharide side-chains [16, 42] , which have a variable length of five to 20 monosaccharides and may in turn account for up to 80% of the molecular weight of the mucins [8, 9] . The mucin domains of gel-forming mucins can reach a length of~550 nm, as estimated for MUC2 and MUC5B [15] , two of the most predominant mucin types in the GI tract and in the airways, respectively [4, 18] . The flanks of the polypeptide backbone are endowed with cysteine-rich regions [44] , which serve to establish inter-mucin disulfide bonds [45] , creating a three-dimensional, covalently-linked mesh-like network which gives mucus its particular viscoelastic trait.
How the mucus barrier works
Mucus acts as a barrier for most of the molecules that enter the hydrogel matrix. The diffusion barrier function is mainly governed by two mechanisms. First, mucus acts as a physical filtering barrier for nanoparticles and any other entities (e.g. viruses, but also molecules) with a bigger size than the mesh-spacing of the mucin network. Second, due to its complex chemical composition, mucus can also slow down the diffusion of molecules smaller than the mesh spacing (physicochemical interaction barrier, Fig. 1 ) [46, 47] . The mucus layer also undergoes a steady renewal and is constantly shed from mucosal tissues, setting a limited time-frame for drug delivery (dynamically rebuilt barrier).
Physical filtering barrier

Mucus rheology
To fulfill its biological functions, mucus relies on its viscoelastic properties, which are tightly regulated by the extent of covalent (disulfide bonds) and non-covalent interactions that take place within the gelmatrix. Despite of its high water content, mucus does not display a Newtonian behavior and is characterized by a shear-thinning viscosity [48] [49] [50] . Hence, a single viscosity value might not be enough to Table 1 Principal characteristics of mucus secretions. .4 [14, [21] [22] [23] [24] [25] [26] Layer thickness (μm)~1 00-800~5-100 -~0.025-1 [5, 14, [27] [28] [29] [30] [31] [32] [33] [34] Clearance mechanism/time Peristalsis/turnover: 1-4 h Ciliary beating and coughing/Clearance rate: 2.5-20 mm/min Intra-abdominal pressure and abdominal motion/clearance time: unclear, few h Eye-blinking/clearance time: 5-10 min [4, [34] [35] [36] [37] [38] [39] Schematic picture -characterize the mechanical properties of mucus, and therefore additional rheological parameters such as the elastic or storage modulus (G ′) and the viscous or loss modulus (G″) are usually given to describe mucus hydrogels in more detail [50] [51] [52] (see Lai et al. [53] for a comprehensive review of mucus rheology). G′ is a measure of the energy stored by a material following a given deformation. G″, however, represents a measure of the energy dissipated in a material following a deformation. At low (physiological) shear/stress levels, G′ generally has a higher magnitude than G″ (G′ N G″, elastic dominant). However, if the shear is sufficiently increased, the mucus gel will undergo a transition to a viscous dominant (G″ N G′) behavior and will eventually deform irreversibly [54] . For instance, as a response to the relatively low shear exerted by the airway ciliary beating on the mucus gel, the interconnected mucus fibers stretch rather than detangle. When the traction of the cilia ceases, the fibers can partly regain their original shape. For this process, the energy exerted on mucus by the cilia is stored by the gel-matrix, and mucus primarily undergoes elastic deformation. Conversely, during coughing, the shear forces are high enough to detangle the fibers of the mucus gel, at least in part, resulting in outward mucus flow over a longer distance. This characteristic viscoelastic trait, together with the adhesive forces, allows mucus to undergo a constant, unidirectional clearance process.
Gastro-intestinal
Mesh-spacing or pore-size
Even though the bulk viscosity of mucus at the macroscale is threeto four orders of magnitude higher than the viscosity of water, the mucus layer is permeable not only to small molecules and nutrients but also to macromolecules, viruses, and certain nanoparticles [55] [56] [57] . Saltzman et al. showed that the diffusion through vaginal mucus of antibodies with a size of up to 15 nm was only reduced by 10-30% compared to their diffusion in water [55] . Further investigations in this direction demonstrated that Norwalk and Human Papilloma Virus-like particles with sizes of 38 and 55 nm, respectively, could freely diffuse through midcycle CVM mucus at similar diffusion rates as in water, while the diffusion of Herpes Simplex Virus, with a size of 180 nm was strongly hindered [56] . Taken together these studies showed a size-dependent steric filtering of mucus and demonstrated the relatively low viscosity of the fluid that fills the pores of the mucin meshwork. Schuster et al. compared the bulk viscosity of undiluted tracheal mucus, to the viscosity of the fluid filling the pores of the mucin network, which was extracted by intensive centrifugation [58] . At the bulk level, as determined by a conventional rotational rheometer, mucus had a complex viscosity magnitude 13,000 times that of water. At the nanoscale, however, the viscosity of the fluid filling the pores of the mucin network, determined by particle tracking, was only three times higher than that of water. This discrepancy between the macroand the micro-rheology of mucus is very interesting from a drug delivery perspective and sets the rationale for the use of nanocarriers for mucosal drug delivery. Therefore, information about the pore size is necessary to understand the size-limitation imposed by mucus to drug delivery.
Estimations of the pore-size have been traditionally derived from electron microscopy (EM) images, reporting an average mesh-spacing of 100 nm (range for CVM [55, 56] ,~200 nm for intestinal mucus [59] , and a range between 100 and 400 nm for CF sputum [60] . Although these estimations provide a first insight into mucus microstructure, it is currently acknowledged that EM images might introduce a bias in the analysis of the subject due to the harsh conditions to which mucus is exposed during sample preparation [46, 58] . This, in turn, might under-or overestimate the magnitude of the mesh spacing (Fig. 2) . Fig. 2 . Differences in the ultrastructure of human tracheal mucus as a function of sample preparation. The photomicrograph in A was obtained with a cryogenic electron microscope; the sample was submerged in liquid nitrogen, fractured, and imaged at low temperature. In B, the mucus sample was fixed with glutaraldehyde and dehydrated with increasing concentrations of ethanol before being transferred to the scanning electron microscope (SEM). In C, the mucus sample was directly placed in a SEM stub, freeze-dried in situ, and transferred to the SEM. The mesh structure is preserved in all samples, but the pore-size shows a significant discrepancy. To determine the scale a simulated yellow sphere with a diameter of 500 nm has been added to all photomicrographs. Fig. 1 . Schematic representation of the filtering properties of the mucus barrier. The size filtering mechanism of mucus is depicted on the left side: purple particles have a bigger size than the mesh spacing between mucus fibers and are therefore trapped within the network. On the other hand, green particles, with a smaller size than the mesh spacing could theoretically diffuse through the pores. However, the interaction filtering mechanism of mucus, depicted on the right side, allows adsorbing particles with a smaller size than the mesh spacing through different interactions. Particles can bind directly to mucins, for example by electrostatic interactions, or can be adsorbed to the mucus network by an indirect binding mediated by nonmucin proteins and other mucus constituents.
The pore-size can be better estimated by mechanically dispersing fluorescent tracer nanoparticles within native mucus samples and tracking their movement using video microscopy [34, 61, 62] . In this regard, particle tracking experiments have generally shown that at a cut-off size of 500 nm, nanoparticles are sterically trapped in mucus, irrespective of their surface chemistry. The mobility of smaller particles, however, largely depends on their surface chemistry [34, 61, 63] . For stealth, polyethylene glycol (PEG)-coated nanoparticles in the 100-200 nm size range, the diffusion coefficients through mucus are relatively high, indicating a compatible mesh-spacing with this particular size range. Exceptionally, Lai et al. showed that PEG-coated 500 nm polystyrene nanoparticles could be transported through CVM at relatively high diffusion rates, highlighting, once again, the differences between mucus secretions across different epithelia [64] . Applying the obstruction-scaling model the mean pore sizes of CVM, CF sputum, and rhinosinusitis mucus have been estimated to be 340 ± 70 nm, 140 ± 50 nm (range 60-300 nm), and 150 ± 50 nm, respectively [64] [65] [66] .
Nevertheless, due to their inhomogeneity mucus gels cannot be adequately characterized by just a mean pore size value, but are better described by a broader pore size distribution. Moreover, mean pore-size estimations based on the application of mathematical models to particle tracking experiments assume a homogeneous distribution of the mechanically dispersed tracer particles, which according to our experience is not always the case. Indeed, during tracking experiments relatively large areas with an absence of fluorescence, from which the tracer particles seem to be sterically excluded, can be observed. This suggests an even smaller pore-size in these regions. A further limitation concerning the understanding of the mesh-spacing of mucus is the fact that poresize estimations are mainly derived from experiments performed under static conditions. Mucus, however, is in constant motion and the mucus fibers continuously stretch and relax. Under dynamic conditions one expects the mesh spacing between neighboring fibers to fluctuate, enabling transient non-covalent interactions between fibers.
Complementary to the mesh-structure created by secreted gelforming mucins, membrane-tethered mucins, on the other hand, play a relevant role in the configuration of the glycocalyx and protect the apical epithelial surface [15] . This protective function of membrane-tethered mucins might impose an additional barrier for drug delivery. In this regard, Button et al. have proposed that a periciliary brush composed of mucins and mucopolysaccharides densely tethered to the surface of bronchial cells, creates an exclusion barrier from which the gelforming mucins would be sterically excluded [67] . Interestingly, fluorescent beads with a size of 40 nm were also excluded from the periciliary space.
Physicochemical interaction barrier
The great variety of functional groups occurring in a mucus gel complements the size-filtering mechanism with a selective physicochemical barrier. The structural domains of mucin molecules provide a wide range of possibilities to interact with molecules of hydrophilic as well as hydrophobic nature. This phenomenon is often addressed by the term interaction barrier of mucus.
Direct binding to mucins
The structural motifs of mucins include highly glycosylated, hydrophilic PTS sequences, non-glycosylated protein regions forming hydrophobic, globular structures, and cysteine-rich regions for stabilization and crosslinking of mucins (Fig. 3) [68, 69] . The oligosaccharide side-chains have a net anionic charge due to the prevalence of sialic acid as the terminal residue as well as the addition of sulfate to Nacetylgalactosamine and galactose [16, 46] . The pKa for sialic acid and sulfate ranges between 2.0 and 2.6 and 2.0-2.5, respectively [70] . At pH values above pH 3, the vast majority of these groups is deprotonated and negatively charged. Therefore, pH is a factor which influences the hydrogel properties and modulates the barrier function. The overall negative charge of the oligosaccharides also serves to stabilize the mucin network through repulsive forces. MUC5B has been described to exist in low-and high charge glycoforms, which are produced by two subpopulations of the mucous cells in submucosal glands [71] . Drug binding to mucins can then occur as a consequence of different charges and in particular for cationic substances by interacting electrostatically with the negatively charged sugar groups. Anionic substances can bind to less frequent, but also present cationic residues, although the repulsion force is the overall governing force in such interactions. Mucus contains various functional groups which can participate in hydrogen bonding, including hydroxyl, carboxylic, and sulfate groups from glycans and amide groups from the peptidic backbone [72] . Electrostatic binding and hydrogen bonds are usually relevant for polar, hydrophilic substances. Van der Waals interactions, however, are resulting from induced electric dipoles which can be present in polar as well as in non-polar molecules [73] .
The non-glycosylated areas of the mucin protein backbone may interact with hydrophobic molecules. The energy required to keep hydrophobic molecules in a cage of surrounding H 2 O molecules is favoring aggregation with other non-polar molecules and structures [73] . Hydrophobic aggregation can also be stabilized by van der Waals forces. This binding mechanism is especially affecting drugs with high hydrophobicity and poor or incomplete dissolution, resulting in hydrophobic aggregates, larger size, and higher multivalence [74] . Molecules with sulfhydryl groups (− SH) are capable of forming covalent bonds with cysteine-rich subdomains of mucus glycoproteins via thiol-disulfide exchange reactions [75] .
With the exception of the disulfide bonds, all the aforementioned bindings are low affinity bonds. Typical energy values for such low affinity bonds are 1.5-2.6 kcal/mol (H-bond),~1.5 kcal/mol (electrostatic interaction), and 0.5-1 kcal/mol (Van der Waals interaction) [73] . Therefore, the low binding affinity of a single bond allows a relatively fast dissociation. Small molecules with a limited number of binding possibilities are merely reduced in diffusion by such interactions. On the other hand, larger macromolecules and particles with several interacting functional groups can be retained within the mucus network due to multivalent binding.
2.2.1.1. Interaction of mucus with small molecule drugs. The diffusion of hydrogen (H + ) through gastric mucus is a paradigmatic example of how small size alone does not grant a free diffusion through mucus [76] . There is a pH gradient between the outermost mucus layer of the stomach, in close contact with the acidic lumen (pH 1-2), and the cell surface (neutral pH) [15, 77] . To keep the pH gradient, the interplay of two mechanisms have been proposed: on the one hand, the enterocytes steadily release bicarbonate for neutralization [77] [78] [79] , and on the other hand, as demonstrated by Li et al., the diffusion through mucus of H + can be slowed down by a transient binding of H + to mucin glycoproteins [76] . Also, electrolytes with a positive charge such as Fe 3+ , Ca 2+ have a 2-10 fold decrease in their permeability through mucus compared to aqueous media, which is attributed to immobilization [80, 81] . Drug molecules having a sufficiently small size, limited hydrophobicity, and no enzymatic degradation are not much limited in their permeation through mucus (Lipinski's rule of five may be a good first approximation) [82] . Early studies, mainly performed between the late 70s and early 90s, investigated the effect of mucus on the permeation of small drug molecules with different physicochemical characteristics motivated by the aim of oral application.
Bhat et al. investigated the effect of drug properties on their mucus permeation, not only molecular weight (MW) but also water solubility and charge [83] . They studied the extent of binding of six selected compounds (albuterol, rifampicin, p-amino-salicylic acid, isoniazid, pyrazinamide, and pentamidine) to mucus glycoproteins. These compounds had a rather low molecular weight (MW b 900 kDa), and only a few charged groups. Their results showed an overall decrease in diffusion for all the molecules through the mucin solution compared to their diffusion through the aqueous solution, irrespective of their molecular properties, suggesting that binding to gastric mucus glycoproteins is non-specific in nature. This study highlighted the ability of mucus to interact with small molecules with diverse chemical nature.
Wikman-Larhed et al. compared the diffusion coefficients of a radiolabeled set of small MW model drugs (glucosamine, mannitol, glucuronic acid, glucose, metoprolol, antipyrine, propranolol, hydrocortisone, and testosterone) through purified gastric mucus and native intestinal mucus [84] . The results displayed a significant difference in terms of the diffusion of the permeation through native pig intestinal mucus and purified mucin mixtures. The authors found significant effects of reduced permeation correlated to lipophilicity and to a lesser extent to the charge (mostly cationic). Further work by Wikman-Larhed et al. with a selected array of molecules with LogK values ranging between − 3.1 and 3.3 confirmed the reduction of the diffusion of lipophilic model drugs, indicating that not just mucins but other mucus components such as lipids play an important role in establishing drugmucus interactions [85] . Indeed, the biochemical characterization of native porcine gastric mucus showed a dry weight composition of just 5% (w/w) mucins, 37% (w/w) lipids, 39% (w/w) proteins, and 6% DNA.
Interaction with macromolecules and nanoparticles.
For larger drug macromolecules and nanoparticles, yet compatible with the mesh spacing of the mucus gel, the diffusion through mucus becomes further challenging. Desai et al. investigated the MW cut-off allowing a passage through mucus. For that purpose, they compared the diffusion of radiolabeled Na and four additional macromolecules through mucus, with MW ranging between 126 and 186,000 Da. No apparent molecular weight cut-off could be determined for the absolute retention of the model drugs, although for macromolecules with a MW above 30,000 Da the diffusion was greatly limited by mucus compared to aqueous media [86] . Their conclusion on the retardation of large MW macromolecules was that "mucus can be regarded as a gel with finite pores". Olmsted et al. showed that small virus-like particles could diffuse unimpeded through CVM, whereas the diffusion of IgM was slowed down by mucus. The authors suggested that the IgM could make low affinity bonds with mucins, which accounts for a slowed diffusion [56] . Larger drug molecules may, in turn, display several functional groups which might account for a stronger binding and prolonged, although still transient, interactions with mucus constituents. As a matter of fact, multivalency in low-affinity interactions is a typical pattern for recognition of biomolecules [87] [88] [89] .
Drug-loaded nanoparticles are prone to be affected by the chemical filtering mechanism of mucus. Several studies have used microscopic techniques, including particle tracking and fluorescent recovery after photobleaching (FRAP), in order to examine the impact of charge and the hydrophilicity/hydrophobicity of nanoparticles on their overall mobility in mucus [52, 61, [90] [91] [92] [93] [94] . A consistent conclusion of these studies is that high surface cationic charge, irrespective of the nanoparticle size, immobilizes the particles by strong binding to negatively charged mucins. Bhattacharjee et al. have recently demonstrated that even 10 nm cationic nanoparticles, which a priori would be compatible with the mucus' pore size, are immobilized by jejunal mucus. Negative charge alone, however, does not grant mucus permeation. Negatively charged nanoparticles with a hydrophobic core in a range between 100 and 200 nm are also strongly immobilized by mucus [58, 62, 95] , whereas for the same type of particles densely coated with PEG, the transition from negative to neutral charge significantly increases their diffusion through mucus by enhancing their hydrophilicity [34, 58] .
Binding to non-mucin elements of mucus
Mucus acts as a reservoir of molecules with important homeostatic and immune functions. For instance, the nasal and intestinal mucus proteome contains at least~110 and~50 proteins, respectively [96, 97] . In nasal mucus, over 50% of the identified proteins are associated to the innate and acquired immunity. Weak, transient interactions between mucin fibers and immune proteins prolong their residence time within the gel matrix without compromising their biological recognition function [98] .
Antimicrobial peptides (defensins, histatins, collectines, etc.), lytic enzymes (lysozyme, amylase, etc.), surfactant proteins A and D (Ctype lectins), and antibodies (secretory IgA or IgG) are some examples of immune mediators found in mucus [99] . Some defensins have a direct bactericidal activity and play a role in the regulation of the microflora (commensal or pathogenic) [11] . Other defensins lack a direct bactericidal activity but can retain bacteria and potentially drug-loaded nanoparticles indirectly, as Chu et al. have demonstrated [10] . They showed that the human defensin 6, without any known direct bactericidal function, can form fibrils and nanonets which surround and entangle bacteria [10] . Surfactant proteins A and C can bind carbohydrates from pathogens in a calcium-dependent manner [100] . Also, Ruge et al. showed that these proteins could adsorb to the surface of polymeric particles and mediate in macrophage uptake [101, 102] .
Trefoil peptides are a class of mucin-associated proteins. For instance, TTF2 protein is mainly expressed in the gastric epithelium and binds MUC6 for gastric mucus stabilization by non-covalent lectin interaction [103] . Globular proteins have also been shown to have a relevant role regarding complexation and biophysical gel properties [104] . Such linker proteins can be covalently or non-covalently bound to mucin fibers and mediate stronger mucin interaction; moreover, they can reduce the permeation of pathogens as well as the diffusion of drugcarriers and larger molecules. All these molecules contained within mucus can thus eventually bind to therapeutic carriers and can also contribute to their adsorption within the mucus matrix. Even if the diffusion is only partially diminished, it can have an impact on the overall drug bioavailability due to the limited time window set by the mucus turnover and clearance, and by the chemical degradation processes of the enzymatic milieu. The dynamics of the mucus gel as well as the size and the interaction filtering are further key factors to be taken into account in mucosal drug delivery.
Dynamic barrier: mucus turnover and clearance
The clearance function of mucus in wet epithelia provides an effective removal of trapped materials. Fresh mucus components are continuously replenished through constant and coordinated mucus secretion and shedding. Thus, in addition to its filtering mechanism, mucus is also a dynamic barrier with a steady turnover. For drugs with slow diffusion mucus clearance sets a limited time-frame for an efficient delivery.
Mucus is constitutively synthesized and secreted at mucosal surfaces by epithelial cells and mucous glands located in the submucosal connective tissue [15, 105] . Specialized mucus-secreting cells, i.e. goblet cells, are intercalated between epithelial cells and are responsible for the renewal of the mucus layer. In addition, mucus is continuously shed from mucosal surfaces by mechanical processes such as peristalsis (gut), eye-blinking (eyes), mucociliary clearance and cough (airways), or by abdominal motion (cervicovaginal tract). Mucus also undergoes extracellular enzymatic degradation. The packing density, adhesiveness, and hence transportability of the mucus gel is affected by enzymatic degradation of the mucins. Among others, proteases, peptidases, glycosidases, sulfatases, glycosulfatases, and esterases are enzymes which potentially could participate in mucin degradation, either by cleaving the carbohydrate side chains or by degrading the protein backbone [106] . One part of these enzymes is endogenously secreted either to intentionally cause the detachment of MUC2 from small intestinal cells [107] or to convert the densely packed inner mucus layer of the colon to the expanded looser layer [108] . The microbiota participates in mucin degradation with enzymes from exogenous (prokaryotic) origin, in particular in the gut (Fig. 4) . Commensal bacteria contribute to mucus degradation by exoglycosidases [109] . Usually, in intact microflora habitat, this is a sequential process of first deglycosylation of the mucins, which further enables the access of enzymes like endoglycosidases and proteases. Protease cleavage depolymerizes the mucin network and has an impact on mucus rheology and turnover [110, 111] . Degradation products, glycans, and peptidoglycans principally, may serve as nutrition for the microflora, may be absorbed and recycled by the epithelium, or may be cleared from the body by the physical transport. Pathogenic bacteria also use enzymes like sialidase, glycosidases, elastases or hydrolases to subvert the mucus barrier [112] . In low colonized mucosal tissues such as the airways (lungs) and the eyes, the endogenous enzymes dominate.
A total volume of around 10 l of mucus is secreted each day in the GI tract, with the largest part is digested and recycled [46] . The exact turnover of mucus in the GI is difficult to determine, but in an isolated perfused intestinal loop in the rat, mucus turnover time could be estimated between 47 and 270 min [35] . Another approach to investigate the mucus turnover and layered structure in mouse colon was to pulse (intraperitoneal injection) labeled, glycosylated molecules that could be further incorporated into newly secreted mucins during glycoprotein biosynthesis [36] . A fluorescent label allowed studying the location of newly produced mucus in histological sections at predetermined time points. The study determined a thickness of 50 μm for the colon inner mucus layer and a total colonic mucus layer thickness of~200 μm. Continuous release of new MUC2 sheets from goblet cells led to a renewal time of 1-2 h of the lamellar, structured, bacteria-free inner mucus layer. The strong background staining of the outer, loosely packed mucus layer did not allow determining the time needed for the conversion between the inner and outer layer [36] . In humans, the colonic mucus layer was measured 400-800 μm, with a dimension of 100-200 μm for the inner mucus layer [5, 113] . A simple calculation of the dimension of the barrier and the turnover allows an estimate of a time window of a few hours for the effective penetration of drug molecules. Nevertheless, this simple approach may fail to consider physiological (e.g. diet) or pathophysiological (e.g. inflammatory) condition. For instance, qualitative differences of the inner mucus layer have been shown for colitis [113] .
Epithelial cells have a glycocalyx structure which consists of cell membrane anchored mucins. The glycocalyx with its stiff, rodlike glycan-rich domains is also a diffusion barrier of approximately 0.5-1.5 μm extension [109] . Oligosaccharides from the jejunal glycocalyx have a turnover time of six to twelve hours. MUC1 is constantly internalized and recycled (0.9% of surface fraction/min) via clathrin-mediated endocytosis [114] . Mucus and glycocalyx turnover is significantly faster than epithelial cell turnover, which is reported to need three to seven days [97] . The turnover times are in correlation with the mucus layer thickness, with the fastest turnover for thinner layers as in the eyes. The organ specificity of mucin types and the distinct biological functions of the mucus layers, however, suggest that structural differences may be beneficial to specific roles.
In the airways, the primary mucus clearance mechanism is the mucociliary clearance [115] . This mechanism is accomplished by the high-frequency, synchronized action of the cilia on the surface of the epithelial cells. Mucociliary clearance enables the rapid transport of inhaled particulates and endogenous materials entrapped within the mucus gel out of the lungs [116] . The airway mucus blanket is organized in two differentiated layers with different biophysical properties. The outermost mucus layer, at the air-liquid interface, is built up by secreted gel-forming mucins and has a high viscosity as well as a mesh-like structure suited for the protection of the epithelia. Underneath, a rather watery, low viscosity liquid layer of just a few micrometers fills the periciliary space and allows for the cilia to beat and recover [117] . A good estimate of the dimensions of the periciliary space is given by the length of the cilia, which falls around five to seven micrometers in the trachea and two to three micrometer in smaller bronchi [118] . Mucus hydration as well as ciliary beat frequency, are governed by Ca 2+ and cAMP signaling, which modulate the coordination of these two parameters for an efficient clearance [119] . The mucociliary clearance rates in healthy, non-smoking humans show a relatively high inter-subject variability with reported average values ranging between 3.6 and 11.4 mm/min in the trachea [120, 121] . The clearance rate seems to diminish towards the lung periphery [118] , and therefore, particles landing deeper in the airways will have a longer lung-residence time. In vivo studies achieved similar mucociliary clearance rates [37, [122] [123] [124] . Hoegger et al. insufflated tantalum disks (350 × 25 μm, 15-20 disks per animal) to intubated newborn piglets and acquired three-dimensional high-resolution images of the chest wall for ten minutes, at 15 s intervals, in order to tract the trajectories of the particles [39] . They reported a highly variable mean particle speed ranging from almost no movement to rates around 16 mm/min. Moreover, the study showed that the ciliary motion favored the transport of the particles to the ventral tracheal surface, which the authors assumed to facilitate the expulsion of the particles out of the lung. Kirch et al. investigated the effects of particle size and the surface chemistry on the mucociliary clearance in an ex vivo embryonic chicken trachea model with fluorescence microscopy [125] . In their study, they deposited (via atomization) nano-and microparticles with different surface chemistries with a size range covering 150-6000 nm onto the tracheal surface. They reported an equivalent horizontal clearance rate of approximately 2 mm/min for any particle irrespective of their size and surface chemistry. Moreover, they could not observe significant penetration of the particles into the mucus layer. The authors concluded that the diffusional transport of the particles into mucus (penetration) was several orders of magnitude slower than the mucociliary clearance rate [125] . With such clearance rates, inhaled therapeutics with attenuated diffusion could be cleared in an approximate time window of 20-360 min, depending on the airway generation in which the aerosol particles deposit (Fig. 5) . Nevertheless, this might not be entirely accurate since inhaled particles depositing in the airways remain in the lungs up to several days. Möller et al. investigated the mucociliary clearance in 13 non-smoking healthy subjects [126] . In this study, the volunteers inhaled homodisperse ferromagnetic iron oxide particles with an aerodynamic diameter of 4.2 μm via the shallow bolus technique aimed at airway deposition. The particles were further detected by magnetopneumography. The authors distinguished between fast and slow airway clearance phases. The fast phase, which they associated with the mucociliary clearance removed 25% of the particles after 3.0 ± 1.6 h and roughly 50% within the first 24 h. The remaining fraction was cleared slowly and remained in the lungs for several weeks, which the authors partly attributed to the deposition of the iron-oxide particles directly in the periciliary fluid of areas of poor mucus coverage [126] .
In disease states such as CF, chronic obstructive pulmonary disease (COPD), asthma or primary ciliary dyskinesia the mucociliary clearance is severely compromised [118] . In these cases, the residence time of inhaled therapeutics in the lungs is prolonged. Primary ciliary dyskinesia is characterized by low mobility of the cilia which beat in an uncoordinated fashion [127] . In the case of CF, the viscosity of mucus is severely altered [60, 128] . The underlying cause of CF is a genetic mutation of the CF transmembrane conductance regulator (CFTR), which primarily leads to an imbalance of mucus hydration, followed by bacterial Fig. 5 . In the airways, mucus clearance sets a limited time-window for drug delivery. Mucus is continuously propelled out of the lungs by the coordinated movement of the cilia on top of the epithelial cells. When inhaled drug particles land onto mucus, their fate will depend on their physical-chemical properties: large (N500 nm) and/or mucoadhesive particles will most probably show reduced diffusion and will be rapidly removed from the lungs by mucociliary clearance (1). Particles with a size compatible with the mesh spacing of the mucus network (below 200 nm) and with an appropriate surface chemistry (non-interacting) may diffuse through mucus and eventually reach the cell surface (2). Small, uncharged drug molecules can rapidly penetrate mucus and be absorbed by the epithelium (3).
colonization [129] . The viscoelasticity of mucus in CF is further increased by the accumulation of DNA and actin filaments derived from apoptotic neutrophils [130] , and by a further stiffening of the mucin network mediated by the increase of oxidant stress [131] . Consequently, mucociliary clearance is dramatically compromised in CF patients.
Thus, being aware of mucus dynamics at each mucosal epithelium in health and disease is an important consideration concerning the development of drug delivery systems. Drug molecules and drug delivery systems must be able to negotiate the mucus layer to reach their target, yet with a permeation coefficient compatible with the renewal and clearance mechanisms of mucus.
Tools to investigate mucus
Mucus sources
The net influence of mucus in drug transport and absorption is difficult to study in vivo because the complexity of in vivo systems does not allow to distinguish between the effects that can be exclusively attributed to mucus, and the combined effects of the whole mucosal barrier, including mucus, epithelium, and other cellular elements. Therefore, ex vivo mucus samples are often used to study drug-mucus interactions. In this respect, a significant limitation in mucus research is the lack of access to high quality samples of human origin. Except for CF sputum and salivary mucins, the accessibility of reliable mucous gels is rather limited. Human tracheal mucus samples can be obtained with the endotracheal tube method [58, 132, 133] . The tracheal tube of patients undergoing elective surgery and requiring general anesthesia can be harvested after surgery obtaining small amounts of undiluted pulmonary mucus from the distal portion of the tracheal tube. Boskey et al. described a method to collect human CVM using a menstrual collection device that provides an average yield of 0.5 g per sampling procedure [134] .
The accessibility of human GI mucus, however, is further limited and therefore native mucus samples from the stomach and intestines of animals are typically used as a surrogate mucus source [18, 49, 51, 52, 85, 95] . For many studies, mucus samples are obtained from local abattoirs, especially from pigs. The amount of mucus collected with this method is relatively high. The whole mucosal tissue can be harvested, or alternatively, mucus can be directly scratched from the organ of interest and transferred to the lab for experimentation. In the latter case, the epithelial surface must be gently scratched to avoid the contamination of harvested mucus with epithelial cells. A good alternative to abattoirs is to obtain GI tract mucus from in vivo research facilities routinely performing surgery to medium and large size animals [49] . This source might be of advantage since the animals are generally fasted before the surgical procedure, which might reduce mucus contamination by dietary elements. The quality of the harvested samples can be macroscopically evaluated upon collection but should be certified by determining the mechanical properties of the harvested material. At relatively low shear stress levels, mucus samples generally show an elastic dominant behavior (G' N G"), which is typical of cross-linked gels and corroborates the existence of a mesh-like structure (Table 2) .
Purified mucins from the porcine stomach or bovine submaxillary gland are commercially available. Nevertheless, these kinds of mucins lack the capacity of cross-linking (G′ b G″) [50, 139] , even at high concentrations, and therefore they do not resemble the mesh-like structure of mucus, which might have a marked influence on drug diffusion studies [61, 84] . Such mucins are often used as building blocks to develop artificial mucus mixtures intended for drug transport studies [61, 84, [140] [141] [142] . Nevertheless, to achieve the appropriate elastic dominant behavior of mucus, apart from mucins, DNA, and lipids, polymerizing agents are often added to these mixtures [49, 50] . In some other studies, in which the drug transport through artificial mucus is reported, no data on the mechanical properties of their mucus mixtures are provided [143] [144] [145] [146] . If these mucus surrogates fail to create a mesh-like structure, the drug transport rates through such artificial mucus mixtures might overestimate the mucus-diffusing capabilities of drugs, in particular for nanocarriers. Good quality mucins can be obtained by washing the apical surfaces of cultured bronchial cells [137, 147] or from ex vivo mucus samples using purification methods which avoid the use of denaturing agents [12, 148] . Mucins isolated by this method can resemble the elastic dominant behavior of mucus above a threshold mucin concentration.
Cell-based mucus-producing in vitro models represent an interesting approach for drug transport studies. Theoretically, these models allow performing transport studies with/without mucus, which can aid to elucidate the net influence of mucus on drug permeation. Primary cells from patients and healthy volunteers can be regarded as the preferred cell source. For instance, cultured primary bronchial cells can secrete mucus and display ciliary motion [67, 149, 150] . Primary bronchial cells can also be harvested from humans with pulmonary conditions, incorporating the disease phenotype in the culture [151] . Nevertheless, access to primary cells is limited, the variability between donors is rather high, and their culture is expensive. Conversely, cell lines are accessible, they show a passage-dependent reproducibility, and are relatively inexpensive. Calu-3 is a cell-line derived from a sub-bronchial gland that has been widely used to estimate drug-transport rates of therapeutics intended for pulmonary drug delivery [152, 153] . Interestingly, if Calu-3 cells are grown under air-liquid (ALI) conditions, they will differentiate into a columnar epithelium that forms a tight epithelial barrier to paracellular transport [154, 155] . Moreover, under ALI conditions they also secrete mucins, including MUC5AC, forming a rather confluent mucus-like layer on the epithelial surface after approximately two to three weeks of culture [156, 157] . This model can be used to study the influence of mucus on the transport of small drugs and the transport and cellular uptake of nanoparticles [155, 157] .
With regard to the GI tract, the HT29-MTX cell line is a mucin-secreting goblet cell line derived from a human colon carcinoma [95, 158] . Unfortunately, it lacks the ability of displaying tight junctions and it is therefore not suitable for absorption studies with small drugs. In order to develop a more realistic model of the intestinal barrier in vitro, minimally comprising a tight epithelium and a layer of mucus, mucin-secreting HT29-MTX cells have been co-cultured with the absorptive Caco-2 cell line [159, 160] , which does not produce mucus but displays high epithelial barrier properties. Alternatively, in vitro approaches have successfully attempted to supplement with exogenous mucus cell lines that resemble relevant mucosal epithelia but do not secrete mucus. This cell lines include Caco-2 (GI-tract) [49] , CFBE41o-(CF airway) [133] , and TR146 (oral cavity) [161] . However, a common limitation of these latter models is the magnitude of the mucus layer, which is usually markedly thicker than in vivo.
Methods to investigate mucus-drug interactions
The aim of this section is to provide a brief summary of the most relevant experimental approaches used to address drug-mucus interactions. For further information on this subject, the state of the art of the techniques to study drug-mucus interactions has been reviewed elsewhere [162, 163] . Traditionally drug-mucus interactions have been addressed by investigating the transport rate of drugs in diffusion cells. Such systems comprise a) a donor compartment, where a certain concentration of the drug molecule of interest can be added; b) a central compartment with a semipermeable membrane (just permeable to drug molecules), where mucus is placed on and retained by the membrane; and c) an acceptor compartment, which allows repeated sampling and detection of the drug molecule of interest. Using the donorto-acceptor strategy, several methods have been developed by different research groups including side-by-side systems [140] , Franz diffusion cells [164] , Ussing chambers [165] , and Transwell®-based permeation assays [146] . These systems have been used for many decades and are still used in drug permeation studies. When using drug diffusion cells, a diligent experimental design should include a set of control experiments aimed at determining the capacity of the semipermeable membrane to retain drug molecules, in particular, when nanoparticle-based drug delivery systems are tested. The diffusion of nanocarriers through such systems might require longer experimental times, which might lead to a partial dissolution of the mucus layer into both the donor and acceptor compartments.
FRAP has been used to estimate the diffusion through mucus of macromolecules, including proteins and DNA, viruses, and nanoparticles [55, 56, 62, 95, 166] . In this technique, fluorescent molecules are dispersed within mucus and transferred to a laser-equipped fluorescence microscope. The region of interest is then localized, and a short series of pre-bleaching images are recorded at relatively low laser power to define the baseline (100%) intensity. The next step consists of bleaching a defined area by increasing the laser power until the fluorescence of the fluorophores is ablated or at least significantly attenuated (at least a 50% reduction of the baseline fluorescence intensity). The post-bleaching point is set to 0% fluorescence. In the last part of the experiments, the laser power is reduced to pre-bleaching values, and a time-series of photomicrographs is captured to investigate the percentage intensity recovery of fluorescence over time (from 0% to 100%). If the molecules can diffuse through mucus, new, fresh-fluorescent molecules will replace the bleached ones, and the fluorescent intensity will increase over time until the recovery curve saturates at a certain level. Conversely, if particles cannot diffuse through mucus at all, the fluorescence intensity will remain steady after photobleaching (close to 0%). The fluorescence intensity percentage value at which the recovery curve saturates is often referred to as the mobile particle fraction, whereas the remaining percentage represents the immobile fraction. Applying mathematical fits to the recovery curves the diffusion coefficient can be estimated [62, 166] . By using FRAP, however, the obtained diffusion coefficient corresponds to that of the particle ensemble, because FRAP does not consider the particles individually.
To study the diffusion of nanocarriers through mucus, multiple particle tracking (MPT) is a useful technique which allows the simultaneous analysis of 100-300 nanoparticles in a single experiment [167] . MPT considers each particle trajectory individually, providing a high statistical power to each experiment. In this technique, fluorescent nanoparticles are mechanically dispersed in mucus, and their trajectories are followed by means of video microscopy over a short period (usually 1-10 s). MPT experiments are commonly performed with high magnification and high numerical aperture objectives. The image series is captured at a relatively high frame rate (minimally, 40 frames per second). The technique shows optimal results with fluorescent tracer particles above 100 nm [58, 61, 62, 168] . By computing the X and Y position of each particle at each frame of the sequence, the trajectories of the particles can be reconstructed, and the mean squared displacement (MSD) can be calculated. The MSD can also be used to obtain the diffusion coefficient of the nanoparticles [167] . Depending on the surface chemistry and the size of the nanoparticles, the MSD values can also be used to determine further rheological parameters of the surrounding medium such as the viscosity and the elasticity.
The incorporation of mucus into chips is a novel approach with a great potential for drug diffusion studies including small drug molecules or nanoparticles [52, 76, 169] . Such micro-devices require only small amounts of mucus for each experiment, provide a standardized experimental framework with a controlled geometry, and are easily transferred to the microscope.
Current attempts to optimize mucosal drug delivery
Mucosal drug delivery remains an area of active research. Increased awareness of the barrier properties of mucus has led to the development of novel therapeutic strategies. Small, uncharged molecules can diffuse at relatively high rates through mucus. Nevertheless, for other therapeutic compounds which exhibit poor solubility, high hydrophobicity, positive charge, or a high MW, alternative strategies have been developed, including mucoadhesive drug delivery systems [170, 171] , aimed at prolonging the residence time of the drug in the mucosal tissue, and mucoinert drug carriers that pursue an increase of the drug diffusion through mucus [34] .
Mucoadhesion
The sticky nature of mucus is a feature that can be exploited to improve the retention time of therapeutic agents in mucosal tissues, enabling a sustained drug release. In addition, drug encapsulation within drug delivery systems can protect drug molecules against enzymatic degradation [172] . This strategy intentionally looks for an intensified contact between the drug delivery system and mucus, which is usually mediated by different interactions such as hydrogen bonding, macromolecule entanglement, and electrostatic, hydrophobic, or van der Waals interactions [14, 173] .
One of the most prominent cationic polymers with strong mucoadhesive properties is chitosan [174] . Chitosan-based drug delivery systems are retained by the mucus mesh through electrostatic interactions with the negatively charged mucins [175, 176] . Another drugmodification to improve mucoadhesion are thiolated polymers, also known as thiomers, which incorporate reactive thiol (−SH) groups in their surface that form disulfide bonds with the thiol groups of the cysteine residues of mucins [75, 177, 178] . Activated -SH groups, however, can also cleave the inter-mucin disulfide bonds, which might partially enhance the penetration of nanoparticles through mucus [179] . Alternatively, mucoadhesion can also be achieved by physical chain entanglements between polymers and the mucin fibers. For instance, particles containing poly(acrylic acid) (PAA) increase the steric hindrance enhancing their entanglement with mucus (Fig. 6) [180] . Nevertheless, the rapid clearance rates and the steady turnover of mucus put into question the theoretical advantage of mucoadhesion as a method to increase bioavailability. An effective mucoadhesive drug delivery system would, in theory, need to adapt its drug release dynamics to the mucus clearance rate.
A final consideration of the mucoadhesive drug delivery system is their potential to affect the micro-as well as the macro-rheological properties of mucus. Mucoadhesive nanoparticles can simultaneously interact with several mucin fibers regrouping them in thick cables around the trapped nanoparticles, thereby modifying the original mesh-spacing of mucus [168] . The mechanical properties and the microstructure of mucus can also be modified by interacting with polymeric nanoparticles. Bhattacharjee et al. have recently shown that cationic nanoparticles strongly adhere to mucins, increasing the viscoelasticity and the rigidity of jejunal mucus [52] . Moreover, Wang et al. reported an increase in the mesh-spacing of cervicovaginal mucus (CVM) without evident changes of its bulk viscosity after incubating amine-modified 200 nm nanoparticles. The authors attribute the increase of the mesh spacing to a rearrangement of the mucus fibers induced by the interacting nanoparticles [138] . The effects which mucoadhesive carriers might have on the overall mucus bulk viscosity, clearance rate, and mucus microstructure can be expected to be dosedependent and should be considered a safety concern during drug developmental stages.
Mucopenetration
Mucus-penetration strategies mediated by stealth drug nanocarriers which comply with the size and surface chemistry requirements of the mucus barrier have gained growing attention. Coating nanoparticles with PEG (PEGylation) is a common strategy to improve their diffusion through mucus. PEGylation was originally developed to prolong the systemic circulation time of proteins and nanoparticles by shielding their surface from aggregation, opsonization, and phagocytosis, with some Fig. 6 . Several strategies have been used to modify the surface of nanocarriers for an improved drug delivery to mucosal tissues. Mucoadhesive drug delivery systems provide an increased interaction with the mucus layer (A). Positively charged particles (e.g. chitosan) bind to negatively charged mucins based on electrostatic interactions (left side). Particles that incorporate reactive thiol groups (− SH) on their surface attach to mucus by forming disulfide bonds (right side). Carrier systems decorated with polymers like PAA lead to physical chain entanglements with mucus fibers and increase steric hindrance (bottom). Mucus-penetrating systems tend to reduce mucus interaction (B). Highly negatively charged particles avoid mucus interaction due to electrostatic repulsion (left side). Zwitterionic particles are modified with interspersed positive and negative surface charges, producing a net neutral charge that facilitates the diffusion through mucus (right side). PEGylated particles possess densely packed polymer chains that form a hydrophilic protective layer for effective mucus penetration (bottom). The application of mucolytic agents enables the diffusion of drug delivery systems through mucus by altering its structure and decreasing the overall viscosity (C). Encapsulated therapeutic compounds are delivered in combination with mucolytic agents such as NAC (yellow) that reduces disulfide bonds (S\ \S) between cross-linked mucins or DNase (blue) that degrade DNA present in mucus (left side). Particles that are functionalized with enzymes like papain (orange) and bromelain (red) disrupt the mucus gel structure in order to enhance mucopenetration of delivery systems (right side). Recent advances to overcome the mucus barrier comprise self-propagating drug delivery systems or multiple absorption strategies (D). Micrcopropeller structures that mimic flagellated bacteria and are directed by external magnetic fields mediate the penetration through mucus (left side, upper part). Particles incorporating ferromagnetic nanoparticles will be likewise attracted by the magnetic field (left side, lower part). Drug delivery systems that manage both mucus penetration and cell internalization properties are coated with a mucoinert polymer that will dissociate during mucus permeation (right ride, upper part). Epithelial absorption is subsequently facilitated by cell-penetrating peptides (CPP) within the carrier (right side, lower part).
of these developments even reaching clinical approval [181, 182] . Justin Hanes' group successfully pioneered the application of PEGylation as a method to enhance the diffusion of nanoparticles through mucus [57] . PEGylated liposomes, polymeric nanoparticles, and dendrimers with the appropriate size generally show higher diffusion rates through mucus than their uncoated versions [58, 64, [183] [184] [185] [186] . Nevertheless, an efficient PEGylation requires a dense coating of the nanoparticle surface as well as an appropriate PEG polymer length. Wang et al. compared the diffusion of 200 nm polystyrene nanoparticles coated with a dense layer of 2 kDa or 10 kDa PEG through CVM [187] . The effective penetration speed of the particles with the low molecular weight PEG was only 7-fold reduced compared to in water, whereas the nanoparticles coated with the high molecular weight PEG were largely immobilized by mucus, most likely due to entangling of the long PEG chains with mucins [187] . If a nanoparticle is intended for cell penetration, a shortcoming of PEGylation might be that the same mechanism that makes the particles mucoinert might also avoid cell-nanoparticle interactions [57] .
Similar to PEGylation, zwitterionic nanoparticles, with interspersed positive and negative charges on their surface and a net neutral charge, also reduce the adsorption of endogenous biomolecules to the nanoparticle surface [188] . An additional advantage of this type of nanoparticles is the facilitation of nanoparticle-cell interactions. Recently, Shan et al. have demonstrated that nanoparticles coated with the zwitterionic surfactant 1,2-dilauroyl-sn-phosphatidylcholine (DLPC) achieve good mucopenetration and a significantly improved cellular uptake compared to PEGylated nanoparticles [189] . Moreover, the oral administration of DLPC-coated insulin-loaded nanoparticles to diabetic rats was associated with a marked hypoglycaemic response.
Mucolytics
All the chemical bonds occurring in a mucous gel can be chemically disrupted. Indeed, mucolytic agents are commonly prescribed to manage the thick mucus secretions in disease states such as CF or COPD [190] . Rubin reviewed most of the clinically available mucoactive drugs [191] (Table 3) .
Most of these drugs reduce the overall viscosity of mucus and allow for a better mucus clearance. The combined delivery of mucolytics together with other therapeutic compounds has been explored as a method to increase drug bioavailability [192, 193] . Suk et al. explored the use of N-acetylcysteine (NAC) and rhDNase as adjuvant mucolytics for the delivery of highly compacted DNA nanoparticles. They could not find a clear benefit in terms of particle diffusivity after rhDNase treatment of CF sputum. However, if NAC alone or NAC + rhDNase were applied to sputum, PEG-coated nanoparticles increased their diffusivity 6-and 13-fold, respectively. Intranasal dosing of NAC prior to particle application markedly increased gene expression in mice compared to control animals that were treated with saline [194] . Taylor-Nordgård et al. improved the penetration of nanoparticles through gastric mucus [95] by applying guluronate oligomers that markedly altered the barrier properties of mucus [12] .
An alternative mucus-disrupting strategy incorporates mucolytic agents to the surface of nanoparticles. In this respect, clinically available mucolytic agents such as DNase, or proteolytic enzymes (e.g. bromelain or papain) have been used to decorate the surfaces of nanoparticles to enhance their mucopenetration [194] [195] [196] . DNase cleaves in a nonspecific manner the DNA accumulated in the mucus of CF patients reducing the overall viscosity of CF mucus. The cysteine proteases bromelain and papain exhibit broad substrate specificity and can cleave the exposed polypeptide regions of mucins. The use of mucolytics can, therefore, improve the penetration of therapeutics, but it must be considered that the use of this strategy will decrease the barrier properties of mucus enabling not only the diffusion of the therapeutic agent but also to viruses and bacteria.
Clinical trials and future perspectives to improve mucosal drug delivery
The preclinical efforts to improve the mucosal administration of carrier-based drug delivery systems have led to the clinical testing of some developments. In 2015 Alton et al. reported the outcomes of a phase 2b clinical trial on the non-viral CFTR gene therapy in CF patients [197] . The study showed a significant, yet modest improvement in the forced expiratory volume (primary outcome) in the intervention group after monthly administration, for one year, of the plasmid DNA, encoding the CFTR gene complexed with a cationic liposome. From the current mucosal drug delivery perspective, the cationic liposomes used in CF clinical trials [197] [198] [199] can be regarded as mucoadhesive with a high chance to be trapped within the mucus layer before they can reach their intracellular target. It is therefore possible to hypothesize that new generation mucopenetrating delivery systems might improve the transfection efficiency in future trials.
The mucus penetrating particle technology, based on the principle of developing stealth nanoparticles for mucosal delivery, has achieved promising in vivo results in the field of non-invasive ocular delivery [200] . This technology was adapted to deliver loteprednol etabonate in order to reduce inflammation and pain in patients undergoing eye surgery; it is currently being tested in a phase 3 clinical trial (NCT02793817).
Recent clinical developments as listed on ClinicalTrials.gov show that most of the mucus-related clinical studies still focus on the respiratory tract (Table 4) . These studies can be subdivided into three groups. The majority are studies focus on mucus secretion and clearance, usually targeting cystic fibrosis (a detailed list is available online at www.cff. org). The second group encompasses studies that instigate basic research including in vitro-in vivo correlations. The last group is linked to diagnostic investigations. Mucus samples from patients might, therefore, help in the diagnosis of certain diseases. Hill et al. suggested the solids concentration in mucus as a biomarker for airway diseases [137] . Similarly, sputum from patients was successfully used to identify lung cancer by microRNA biomarkers [201] , and proteome analysis of cervical mucus can serve as a non-invasive method for the diagnosis of endometriosis [202] .
Future developments in the field of mucosal drug delivery should be directed at increasing the diffusion as well as the efficiency of therapeutics. For that purpose, gaining further knowledge of how therapeutics interact with mucus at the molecular level is of major relevance. In this respect, Li et al. have recently investigated the electrostatic interactions between mucins and small synthetic peptides with controlled spatial arrangements of anionic and cationic charges [169] . Using a microfluidics-based diffusion test, they could show a different mucin-peptide interaction pattern of two net neutrally-charged peptides with identical amino acid composition, but with a different spatial arrangement of the positive and negative charges. The transport of the peptide with interspersed charges was markedly different compared to the peptide with the charges polarized in blocks. Thus, the diffusion through mucus of small, electrostatically-interacting molecules could be theoretically improved by tuning, when applicable, the spatial distribution of its charges. This principle is also applied in the design of zwitterionic nanocarriers, which have been already shown to efficiently address the mucus barrier in vivo [189] . Alternative shapes of classic spherical nanoparticles could also improve mucopenetration. Yu et al. have recently proposed that cylindrical nanorods are transported at higher rates through mucus compared to spherical nanoparticles. They partly attributed this finding to the rotational dynamics of the particles and the local shear flow exerted by the nanorods [203] . The high limitation imposed by mucous gels to drug diffusion, in particular to nanocarriers, could be theoretically overcome by self-propagating drug delivery systems. Recent advances in this field include the use of externally guided magnetically-driven microrobots such as inorganic micropropellers [204] and magnetotactic bacteria (MTB) [205] . Interestingly, MTBs are self-propelled by their flagella and can be directed to a reference position in a magnetic field.
In the case of nanocarrier-based drug delivery systems intended for cell internalization, a special focus should not only be set to crossing the mucus layer but also to improving cell-carrier interactions. This is often achieved by decorating nanoparticles with cell-penetrating peptides (CPP) [206] . Nevertheless, their cell penetration enhancing effects can be masked by the biomolecular corona formed around the nanoparticles upon their contact with biological media [207] . The type as well as the number of biomolecules that adsorb to mucus penetrating nanoparticles still remains to be elucidated. An elegant approach by Shan et al. to improve the mucopenetration and the cellular uptake of nanoparticles consisted of coating a nanocomplex, composed of insulin and a CPP with a dissociable hydrophilic coating (Fig. 6D) [208] . The hydrophilic coating is designed to increase the diffusion of the particles (~170 nm) through mucus. Interestingly, the gradual dissociation of the outer hydrophilic coating during mucus diffusion exposes the CPP to the cell surface thereby increasing the internalization.
The final dosage form as well as the delivery method for each mucosal tissue must be also thoroughly considered. Aerosol delivery of dry powders to the lungs often requires combining therapeutics with excipients to reach a final formulation that will produce aerosol particles with an appropriate aerodynamic behavior [1] . However, the dissolution of such microparticles must comply with the airways' clearance rate. Nanoparticles embedded in a fast dissolving matrix address this issue by providing a fast release of the nanoparticles into the mucus. Ruge et al. were able to show that the disaggregation of such particles does not occur under static conditions, but will only take place if the particles are deposited onto agitated mucus. This finding highlights the relevant role of the shear forces of mucociliary clearance on particle disaggregation [209] . Such a system combined with mucus-penetrating gene delivery systems might be a future perspective for pulmonary gene therapy. Effects of smoking cessation on the airway defense mechanism, airway inflammation and genomics determined by different read outs such as cytokine release, microRNA analysis, mucus physical properties or pH. Seasonal Differences in Nasal Mucus Proteome and Impact of Immunotherapy
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Investigation of seasonal (pollen) changes between allergic rhinitis patients and healthy controls with focus on an immune therapy.
Conclusion
Mucus is a natural hydrogel that acts as a biological barrier in various ways. First, it may act as a physical barrier for particles with a bigger size than the mesh spacing between mucin fibers. Secondly, mucus can also slow down the diffusion of smaller molecules by physico-chemical interaction, including electrostatic and hydrophobic binding. Thirdly, the steady turnover and clearance of mucus sets a limit to the residence time of entrapped molecules and particles at mucosal tissues.
A deeper understanding how the mucus barrier works has already led to the development of different mucosal drug delivery strategies, including mucoadhesion, which exploits the adhesive nature of mucus to prolong the residence time of drugs at mucosal tissues, and mucopenetration, which conversely tries to avoid drug-mucus interactions for deeper mucus penetration. Both strategies have shown promising results in preclinical and clinical trials for certain applications and routes of administration (e.g. buccal, ocular and vaginal). However, the clinical translation of advanced drug delivery systems capable of overcoming the mucus barrier, in particular in places where it undergoes a rapid turnover/clearance or forms a rather thick layer of low-permeability (e.g. the GI tract or airways), still remains a major challenge.
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